Atrogi AB is a Swedish AB based in Solna, operating in the Manufacture of pharmaceutical preparations sector. Incorporated in 2013, the company has 14 employees and reported revenue of SEK 2.0k in its latest annual filing.
Firman tecknas av styrelsen Firman tecknas två i förening av ledamöterna Dessutom har verkställande direktören rätt att teckna firman beträffande löpande förvaltningsåtgärder
Company purpose
Bolaget skall aktivt utveckla behandlingar, instrument och mediciner inom områdena diabetes och fetma samt där tillhörande områden.
In its most recent annual report (2025), Atrogi AB reported revenue of SEK 2.0k, a decrease of 100% on the year before. The figures on this page draw on 5 annual filings covering 2021 to 2025. The bottom line showed a net loss of SEK 25.8m, and the EBITDA margin stood at -1,199,050%.
At the end of 2025, equity financed 72% of the balance sheet, and current assets covered short-term debt 0.2 times.
Frequently asked questions
What is the Org number of Atrogi AB?
Atrogi AB is registered with Bolagsverket / SCB under Org 5569258311.
What is the revenue of Atrogi AB?
Atrogi AB reported revenue of SEK 2.0k in 2025.
How many employees does Atrogi AB have?
Atrogi AB employs 14 people as of the latest annual report.
Who is the CEO of Atrogi AB?
Paul Brian Little is the CEO of Atrogi AB, in role since 2025.
Who is the chairman of Atrogi AB?
Anders Olof Adolf Ekblom chairs the board of Atrogi AB, in role since 2022.
Where is Atrogi AB headquartered?
Atrogi AB's registered address is Tomtebodavägen 6.
